AtheroGenics To Lay Off Half Its Workforce On Heels Of ARISE Failure, AstraZeneca Pullout
This article was originally published in The Pink Sheet Daily
Executive Summary
Initiative will free up funds needed to file NDA on AGI-1067 without former partner AstraZeneca.
You may also be interested in...
Credit Woes Hit Pharma
The biggest pharmaceutical companies are least affected by the current credit crisis due to their strong balance sheets and hefty piles of cash, yet even they are finding debt is more expensive and harder to obtain. Big biotechs also have billions of dollars in cash and marketable securities. Smaller, development stage companies, however, are more fragile because their existence depends on their ability to raise money to fund their R&D.Specialty pharma falls in between big pharma and biotech: the group is vulnerable, but not as much as biotech. The lack of access to capital makes doing deals tougher and more expensive.
AtheroGenics Completes Enrollment Of Phase III AGI-1067 Diabetes Study
Interim data from the randomized, double-blind, placebo-controlled trial are expected in the second quarter of 2008.
AtheroGenics Completes Enrollment Of Phase III AGI-1067 Diabetes Study
Interim data from the randomized, double-blind, placebo-controlled trial are expected in the second quarter of 2008.